Llombart-Cussac, A., Pérez-García, J. M., López-Miranda, E., Xiang, R. R. Z., Sampayo-Cordero, M., Santos, J. C., Boix, O., Beltran, M., Barrios, C. H., Curigliano, G., Bartsch, R., Hardy-Bessard, A., Compagnoni, A., Theall, K. P., Buechele, T., Wasserman, T., Cortés, J. (2025). ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (ELA) + everolimus (EVE) versus ELA + placebo (PBO) in ER+/HER2- advanced breast cancer (aBC) patients with
            <i>ESR1</i>
            -mutated tumors progressing on endocrine therapy (ET) + CDK4/6i.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps1129